Patients will be re-assessed at 4, 12, 24, 36, 48, 60, 72, 84 and 96 weeks post initiation for treatment efficacy, safety, tolerability and compliance. Follow-up blood tests will be drawn to assess virological and immunological response to treatment as well as routine blood tests to detect hepatitis C status, liver/renal toxicities and haematological abnormalities. ECG evaluation for QT abnormalities will be performed at baseline and at weeks 4, 12, 48 and 96. A follow up safety visit will be conducted 4 weeks post completion of therapy. Monitoring for adverse events will take place throughout the study period and continuity of care, as per standard medical care for this patient population, maintained after the patients have completed the study at the respective sites.